القدرات
مصنع واحد. أربعة خطوط قدرات. كتالوج بُني ليتّسع لهما معًا.
تصنّع Naprod حقن الأورام والتخدير والرعاية الحرجة، إلى جانب الأقراص والكبسولات والمكونات الفعالة المرافقة لها، من موقع واحد في Tarapur، ماهاراشترا.
أكثر من 200 منتج في الكتالوج، تغطي صيغ الجرعات النهائية والمكونات الصيدلانية الفعالة، تُصنَّع في ظل ضوابط عمليات EU-GMP وWHO-GMP.
Installed capacity
Seven production lines, one site
Annual installed capacity at 300 production days a year, company-confirmed in September 2026, with dedicated oncology lines kept separate from the general lines.
-
18.3 M
Oncology liquid vials / yr
-
12 M
Oncology lyophilized vials / yr
-
240 M
Oncology tablets and capsules / yr
-
21.6 M
General liquid vials / yr
-
67.8 M
General lyophilized vials / yr
-
60 M
Propofol vials / yr
-
360 K
Inhaler bottles / yr
By capability
Four ways into the plant
Manufacturing is the base capability everything else builds on; lyophilization is the specialization behind Naprod's oncology injectables; R&D covers formulation and analytical development. Quality & Regulatory governs what the plant is permitted to ship, and where.
-
Manufacturing
The Tarapur, Maharashtra production floor behind the 200+ product catalog across finished dose forms and APIs, run under EU-GMP and WHO-GMP process controls.
-
Lyophilization
Freeze-drying at commercial scale: 12M dedicated oncology vials and 67.8M general vials a year, the capability most closely tied to Naprod’s oncology franchise.
-
Research & Development
Formulation and analytical development behind the catalog and the 24-product official pipeline, feeding future filings across SRA, ROW, and domestic markets.
-
Quality & Regulatory
15+ international accreditations on the register, including EU-GMP, WHO-GMP, ANVISA, INVIMA, EAEU, UAE MOHAP, and NHRA Bahrain.